» Articles » PMID: 33080914

Carbon Ion Radiobiology

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Oct 21
PMID 33080914
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Radiotherapy using accelerated charged particles is rapidly growing worldwide. About 85% of the cancer patients receiving particle therapy are irradiated with protons, which have physical advantages compared to X-rays but a similar biological response. In addition to the ballistic advantages, heavy ions present specific radiobiological features that can make them attractive for treating radioresistant, hypoxic tumors. An ideal heavy ion should have lower toxicity in the entrance channel (normal tissue) and be exquisitely effective in the target region (tumor). Carbon ions have been chosen because they represent the best combination in this direction. Normal tissue toxicities and second cancer risk are similar to those observed in conventional radiotherapy. In the target region, they have increased relative biological effectiveness and a reduced oxygen enhancement ratio compared to X-rays. Some radiobiological properties of densely ionizing carbon ions are so distinct from X-rays and protons that they can be considered as a different "drug" in oncology, and may elicit favorable responses such as an increased immune response and reduced angiogenesis and metastatic potential. The radiobiological properties of carbon ions should guide patient selection and treatment protocols to achieve optimal clinical results.

Citing Articles

Carbon minibeam radiation therapy results in tumor growth delay in an osteosarcoma murine model.

Bertho A, Graeff C, Ortiz R, Giorgi M, Schuy C, Juchaux M Sci Rep. 2025; 15(1):7305.

PMID: 40025099 PMC: 11873225. DOI: 10.1038/s41598-025-91872-6.


Irradiation-responsive PRDM10-DT modulates the angiogenic response in human NSCLC cells in an SP1-dependent manner via the miR-663a/TGF-β1 axis.

Huang H, Xu Y, Guo Z, Zhang M, Li W, Song Y J Transl Med. 2025; 23(1):235.

PMID: 40016776 PMC: 11866594. DOI: 10.1186/s12967-025-06273-0.


adioresistant, are, ecurrent, and adioinduced: 4s of Hadrontherapy for Patients Selections.

Vischioni B, Barcellini A, Magro G, Rotondi M, Durante M, Facoetti A Int J Part Ther. 2025; 15:100737.

PMID: 39927286 PMC: 11804719. DOI: 10.1016/j.ijpt.2024.100737.


Advancing Radiobiology: Investigating the Effects of Photon, Proton, and Carbon-Ion Irradiation on PANC-1 Cells in 2D and 3D Tumor Models.

Charalampopoulou A, Barcellini A, Magro G, Bellini A, Borgna S, Fulgini G Curr Oncol. 2025; 32(1.

PMID: 39851965 PMC: 11763791. DOI: 10.3390/curroncol32010049.


Investigating the Local Effectiveness of Carbon Ion Radiotherapy for Unresectable Female Genital Tract Melanomas: A Preliminary Real-World Study.

Barcellini A, Fontana G, Vai A, Aletti G, Charalampopoulou A, Chiellino S Cancers (Basel). 2025; 16(24.

PMID: 39766046 PMC: 11674411. DOI: 10.3390/cancers16244147.


References
1.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

2.
Durante M, Yamada S, Ando K, Furusawa Y, Kawata T, Majima H . X-rays vs. carbon-ion tumor therapy: cytogenetic damage in lymphocytes. Int J Radiat Oncol Biol Phys. 2000; 47(3):793-8. DOI: 10.1016/s0360-3016(00)00455-7. View

3.
Bert C, Engenhart-Cabillic R, Durante M . Particle therapy for noncancer diseases. Med Phys. 2012; 39(4):1716-27. DOI: 10.1118/1.3691903. View

4.
Glowa C, Karger C, Brons S, Zhao D, Mason R, Huber P . Carbon ion radiotherapy decreases the impact of tumor heterogeneity on radiation response in experimental prostate tumors. Cancer Lett. 2016; 378(2):97-103. PMC: 7747017. DOI: 10.1016/j.canlet.2016.05.013. View

5.
Dilmanian F, Rusek A, Fois G, Olschowka J, Desnoyers N, Park J . Interleaved carbon minibeams: an experimental radiosurgery method with clinical potential. Int J Radiat Oncol Biol Phys. 2012; 84(2):514-9. DOI: 10.1016/j.ijrobp.2011.12.025. View